<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179892</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00071635</org_study_id>
    <nct_id>NCT02179892</nct_id>
  </id_info>
  <brief_title>Comparison of Exparel to Bupivacaine With Dexamethasone in TAP Block</brief_title>
  <acronym>TapBlock</acronym>
  <official_title>Comparison Between Bupivacaine Extended-Release Liposome Injection (Exparel) Versus Bupivacaine With Dexamethasone in Transversus Abdominis Plane Block: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colette Curtis MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and duration of bupivacaine
      extended-release liposome injection (Exparel) versus bupivacaine with dexamethasone in
      transversus abdominis plane (TAP) blocks for patients undergoing abdominal surgery at Emory
      University Hospital and Emory University Hospital Midtown.

      The investigators hypothesize that Exparel will provide greater postoperative pain relief
      than bupivacaine with dexamethasone. The investigators plan to enroll up to 50 male and
      female subjects meeting inclusion and exclusion criteria who will be randomized to receive
      either Exparel (Group 1) or bupivacaine with epinephrine and dexamethasone (Group 2) in the
      TAP block to achieve at least 22 subjects in each group
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group 1 will be administered 266 mg of Exparel, diluted to 30 mL. Group 2 will be given 28 mL
      of 0.375% bupivacaine and 8mg/2 mL dexamethasone.Before injection of the study medication,
      2mL of normal saline with be injected under ultrasound visualization to ensure needle tip is
      in the transversus abdominis plane.Randomization will occur following the written informed
      consent and prior to the start of the surgical procedure. Postoperatively, study patients
      will receive intravenous acetaminophen 1000mg every 8 hours for 3 doses, then oral
      acetaminophen 650mg every 6 hours. Subjects will also have patient-controlled analgesia (PCA)
      with morphine or hydromorphone. The research staff recording data will be blinded to the
      treatment group. Demographic data will be recorded, including age, date of birth, height and
      weight to ensure similarity between the two groups. A medical history will be obtained as
      well as surgical and anesthesia details. Study patients will be followed for 72 hours
      postoperatively to record the amount of opioid consumption, as well as other pain score data
      using the Visual Analogue Scale (VAS).The subject's participation will end 72 hours after
      surgery. A telephone interview will occur with the subject if hospital discharge occurs prior
      to 72 hours.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate patient population to complete enrollment
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 6, 2015</completion_date>
  <primary_completion_date type="Actual">June 6, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Opioid Consumption</measure>
    <time_frame>Post Surgery (Up to 72 Hours)</time_frame>
    <description>The investigators will collect the total amount of opioid consumption for the 72 hour post operative period in each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Visual Analogue Scale (VAS) Pain Score at Rest</measure>
    <time_frame>Post-Surgery 24 Hours, 48 Hours, 72 Hours</time_frame>
    <description>The VAS method of pain assessment (scale of 1- 10) will be used to measure the participant's pain level at rest each day during the 72 hours post surgical period. One represents the lowest level of pain and 10 represents the highest level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Visual Analogue Scale (VAS) Pain Score With Movement</measure>
    <time_frame>Post-Surgery 24 Hours, 48 Hours, 72 Hours</time_frame>
    <description>The VAS method of pain assessment (scale of 1-10) will be used to measure the patient's level of pain with movement each day during the 72 hour post surgical period. One represents the lowest level of pain and 10 represents the highest level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time of First Opioid Use</measure>
    <time_frame>Post-surgery (Up to 72 Hours)</time_frame>
    <description>The time of first opioid use after surgery will be recorded for up to 72 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group 1-Exparel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2-Bupivacaine and Dexamethasone IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Extended-Release Liposome Injection (Exparel)</intervention_name>
    <description>266mg/30mL of Exparel will be injected via unilateral TAP block</description>
    <arm_group_label>Group 1-Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine and Dexamethasone Injection</intervention_name>
    <description>As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.</description>
    <arm_group_label>Group 2-Bupivacaine and Dexamethasone IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <description>Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.</description>
    <arm_group_label>Group 1-Exparel</arm_group_label>
    <arm_group_label>Group 2-Bupivacaine and Dexamethasone IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Acetaminophen</intervention_name>
    <description>Oral acetaminophen 650 mg every 6 hours.</description>
    <arm_group_label>Group 1-Exparel</arm_group_label>
    <arm_group_label>Group 2-Bupivacaine and Dexamethasone IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients undergoing scheduled abdominal surgery at Emory University
             Hospital or Emory University Hospital Midtown

          -  Patients willing and able to provide written informed consent

        Exclusion Criteria:

          -  Patients less than 18 years of age, since Exparel has not been studied in this age
             group

          -  Patients who are pregnant or lactating, since Exparel has not been shown to be safe in
             this population, and because of potential drug transfer to child

          -  Patients with uncontrolled diabetes since dexamethasone may cause hyperglycemia

          -  Patients with liver dysfunction, since bupivacaine is hepatically metabolized

          -  Patients with renal failure, since bupivacaine is renally excreted, defined as
             requiring hemodialysis or renal replacement therapy

          -  Patients with allergy to one of the study drugs

          -  Patients with local infection, which may be exacerbated by dexamethasone

          -  Patients with significant opioid tolerance, defined as taking at least 60 mg oral
             morphine per day, 3 mg oral oxycodone per day, 25 mcg/hr fentanyl patch, 25 mg oral
             oxymorphone per day, 8 mg of oral hydromorphone per day or an equianalgesic dose of
             another opioid for one week or longer

          -  Patients with known coagulopathy, since bleeding risk is higher Patients who are
             getting neuraxial anesthesia for surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colette Curtis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <results_first_submitted>July 13, 2017</results_first_submitted>
  <results_first_submitted_qc>July 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2017</results_first_posted>
  <disposition_first_submitted>April 25, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 25, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 28, 2017</disposition_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Colette Curtis MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>anesthesia</keyword>
  <keyword>surgery</keyword>
  <keyword>pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the Emory University Hospital and the Emory University Hospital Midtown between July 2014 through June 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1-Exparel</title>
          <description>Bupivacaine Extended-Release Liposome Injection (Exparel) were administered via TAP block procedure
Bupivacaine Extended-Release Liposome Injection (Exparel): 266mg/30mL of Exparel was injected via unilateral TAP block.</description>
        </group>
        <group group_id="P2">
          <title>Group 2-Bupivacaine and Dexamethasone IV</title>
          <description>Bupivacaine and Dexamethasone Injection were administered via TAP block procedure.
Bupivacaine and Dexamethasone Injection: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone was injected via unilateral TAP block.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1-Exparel</title>
          <description>Bupivacaine Extended-Release Liposome Injection (Exparel) was administered via TAP block procedure
Bupivacaine Extended-Release Liposome Injection (Exparel): 266mg/30mL of Exparel was injected via unilateral TAP block</description>
        </group>
        <group group_id="B2">
          <title>Group 2-Bupivacaine and Dexamethasone IV</title>
          <description>Bupivacaine and Dexamethasone Injection was administered via TAP block procedure.
Bupivacaine and Dexamethasone Injection: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone was injected via unilateral TAP block.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Opioid Consumption</title>
        <description>The investigators will collect the total amount of opioid consumption for the 72 hour post operative period in each group.</description>
        <time_frame>Post Surgery (Up to 72 Hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1-Exparel</title>
            <description>Bupivacaine Extended-Release Liposome Injection (Exparel) was administered via TAP block procedure
Bupivacaine Extended-Release Liposome Injection (Exparel): 266mg/30mL of Exparel was injected via unilateral TAP block</description>
          </group>
          <group group_id="O2">
            <title>Group 2-Bupivacaine and Dexamethasone IV</title>
            <description>Bupivacaine and Dexamethasone Injection was administered via TAP block procedure.
Bupivacaine and Dexamethasone Injection: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone was injected via unilateral TAP block.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Opioid Consumption</title>
          <description>The investigators will collect the total amount of opioid consumption for the 72 hour post operative period in each group.</description>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507" spread="602"/>
                    <measurement group_id="O2" value="392" spread="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Visual Analogue Scale (VAS) Pain Score at Rest</title>
        <description>The VAS method of pain assessment (scale of 1- 10) will be used to measure the participant's pain level at rest each day during the 72 hours post surgical period. One represents the lowest level of pain and 10 represents the highest level of pain.</description>
        <time_frame>Post-Surgery 24 Hours, 48 Hours, 72 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1-Exparel</title>
            <description>Bupivacaine Extended-Release Liposome Injection (Exparel) was administered via TAP block procedure
Bupivacaine Extended-Release Liposome Injection (Exparel): 266mg/30mL of Exparel was injected via unilateral TAP block</description>
          </group>
          <group group_id="O2">
            <title>Group 2-Bupivacaine and Dexamethasone IV</title>
            <description>Bupivacaine and Dexamethasone Injection was administered via TAP block procedure.
Bupivacaine and Dexamethasone Injection: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone was injected via unilateral TAP block.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Visual Analogue Scale (VAS) Pain Score at Rest</title>
          <description>The VAS method of pain assessment (scale of 1- 10) will be used to measure the participant's pain level at rest each day during the 72 hours post surgical period. One represents the lowest level of pain and 10 represents the highest level of pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours Post Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.9"/>
                    <measurement group_id="O2" value="3.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours Post Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.6"/>
                    <measurement group_id="O2" value="3.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours Post Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.0"/>
                    <measurement group_id="O2" value="3.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Visual Analogue Scale (VAS) Pain Score With Movement</title>
        <description>The VAS method of pain assessment (scale of 1-10) will be used to measure the patient's level of pain with movement each day during the 72 hour post surgical period. One represents the lowest level of pain and 10 represents the highest level of pain.</description>
        <time_frame>Post-Surgery 24 Hours, 48 Hours, 72 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1-Exparel</title>
            <description>Bupivacaine Extended-Release Liposome Injection (Exparel) was administered via TAP block procedure
Bupivacaine Extended-Release Liposome Injection (Exparel): 266mg/30mL of Exparel was injected via unilateral TAP block</description>
          </group>
          <group group_id="O2">
            <title>Group 2-Bupivacaine and Dexamethasone IV</title>
            <description>Bupivacaine and Dexamethasone Injection was administered via TAP block procedure.
Bupivacaine and Dexamethasone Injection: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone was injected via unilateral TAP block.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Visual Analogue Scale (VAS) Pain Score With Movement</title>
          <description>The VAS method of pain assessment (scale of 1-10) will be used to measure the patient's level of pain with movement each day during the 72 hour post surgical period. One represents the lowest level of pain and 10 represents the highest level of pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 Hours Post Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="3.4"/>
                    <measurement group_id="O2" value="5.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours Post Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="4.1"/>
                    <measurement group_id="O2" value="6.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 Hours Post Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.9"/>
                    <measurement group_id="O2" value="4.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time of First Opioid Use</title>
        <description>The time of first opioid use after surgery will be recorded for up to 72 hours.</description>
        <time_frame>Post-surgery (Up to 72 Hours)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1-Exparel</title>
            <description>Bupivacaine Extended-Release Liposome Injection (Exparel) was administered via TAP block procedure
Bupivacaine Extended-Release Liposome Injection (Exparel): 266mg/30mL of Exparel was injected via unilateral TAP block</description>
          </group>
          <group group_id="O2">
            <title>Group 2-Bupivacaine and Dexamethasone IV</title>
            <description>Bupivacaine and Dexamethasone Injection was administered via TAP block procedure.
Bupivacaine and Dexamethasone Injection: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone was injected via unilateral TAP block.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time of First Opioid Use</title>
          <description>The time of first opioid use after surgery will be recorded for up to 72 hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="29"/>
                    <measurement group_id="O2" value="46" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the duration of the study (1 year).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1-Exparel</title>
          <description>Bupivacaine Extended-Release Liposome Injection (Exparel) was administered via TAP block procedure
Bupivacaine Extended-Release Liposome Injection (Exparel): 266mg/30mL of Exparel was injected via unilateral TAP block</description>
        </group>
        <group group_id="E2">
          <title>Group 2-Bupivacaine and Dexamethasone IV</title>
          <description>Bupivacaine and Dexamethasone Injection was administered via TAP block procedure.
Bupivacaine and Dexamethasone Injection: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone was injected via unilateral TAP block.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Colette Curtis</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-3900</phone>
      <email>ccurti3@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

